IL27 and prostate carcinoma: Moreover, IL-30, but not EBI3, was demonstrated to be expressed in prostate cancer lesions and tumor-draining lymph nodes, such as CD68+ macrophages, CD33+/CD11b+ myeloid cells, and CD14 monocytes, and its expression correlated with advanced disease grade and stage (68).